- Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soarCNBC
- Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 BillionInvestors | Eli Lilly and Company
- Eli Lilly raises annual forecasts as weight-loss drug quarterly sales cross $1 billionYahoo Finance
- Eli Lilly Lifts 2024 Sales Outlook as Zepbound Demand Drives QuarterBloomberg
- Eli Lilly Reports Earnings Thursday Amid a Stock Slump. Here’s What to Expect.Barron’s